Pure Global

Crosslinking in Infectious Keratitis - Trial NCT03801590

Access comprehensive clinical trial information for NCT03801590 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Infectious Keratitis. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
Device Trial
NCT03801590
Not yet recruiting
Device Trial
device
Trial Details
ClinicalTrials.gov โ€ข NCT03801590
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Crosslinking in Infectious Keratitis
Safety and Efficacy Of Corneal Collagen Crosslinking (CXL) In Infectious Keratitis

Study Focus

Infectious Keratitis

Crosslinking with Riboflavin and UV-A

Interventional

device

Sponsor & Location

Assiut University

Timeline & Enrollment

N/A

Dec 01, 2021

Jan 01, 2023

20 participants

Primary Outcome

Determine the duration for corneal ulcer healing

Summary

Microbial keratitis is an infection of the cornea that is associated with risk of permanent
 visual impairment.
 
 It can be caused by bacteria, virus, fungus, protozoa and parasites. The common risk factors
 for infectious keratitis include ocular trauma, contact lens wear, recent ocular surgery,
 preexisting ocular surface disease, dry eyes, lid deformity, corneal sensation impairment,
 chronic use of topical steroids and systemic immunosuppression .

ICD-10 Classifications

Keratitis
Keratitis, unspecified
Other keratitis
Herpesviral keratitis and keratoconjunctivitis
Keratitis and keratoconjunctivitis in other infectious and parasitic diseases classified elsewhere

Data Source

ClinicalTrials.gov

NCT03801590

Device Trial